The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.

Saved in:
Bibliographic Details
Title: The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.
Authors: Luke JJ; UPMC Hillman Cancer Center and University of Pittsburgh, Pittsburgh, PA, USA. lukejj@upmc.edu., Patel MR; Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA., Blumenschein GR; Department of Thoracic Head & Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hamilton E; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA., Chmielowski B; Division of Hematology & Medical Oncology, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA., Ulahannan SV; OUHSC Oklahoma City, OK/SCRI, Oklahoma City, OK, USA., Connolly RM; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA.; Cancer Research at UCC, College of Medicine and Health, University College Cork, Cork, Ireland., Santa-Maria CA; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA., Wang J; Duke University Medical Center, Durham, NC, USA., Bahadur SW; Banner MD Anderson Cancer Center, Gilbert, AZ, USA., Weickhardt A; Austin Health, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia., Asch AS; OUHSC Oklahoma City, OK/SCRI, Oklahoma City, OK, USA., Mallesara G; Calvary Mater Newcastle Hospital, Waratah, New South Wales, Australia., Clingan P; Southern Medical Day Care Centre, Wollongong, New South Wales, Australia., Dlugosz-Danecka M; Pratia MCM Krakow, Krakow, Poland., Tomaszewska-Kiecana M; BioVirtus Research Site Sp. Z o.o., Jozefow, Poland., Pylypenko H; Cherkasy Regional Oncology, Cherkasy, Ukraine., Hamad N; St. Vincent's Health Network, Kinghorn Cancer Centre, University of New South Wales, School of Clinical Medicine, Faculty of Medicine and Health, University of Notre Dame Australia, School of Medicine, Sydney, New South Wales, Australia., Kindler HL; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA., Sumrow BJ; MacroGenics, Clinical, Rockville, MD, USA., Kaminker P; MacroGenics, Research, Rockville, MD, USA., Chen FZ; MacroGenics, Research, Brisbane, CA, USA., Zhang X; MacroGenics, Research, Rockville, MD, USA., Shah K; MacroGenics, Research, Rockville, MD, USA., Smith DH; MacroGenics, Research, Brisbane, CA, USA., De Costa A; MacroGenics, Research, Brisbane, CA, USA., Li J; MacroGenics, Research, Brisbane, CA, USA., Li H; MacroGenics, Clinical, Rockville, MD, USA., Sun J; MacroGenics, Clinical, Rockville, MD, USA., Moore PA; MacroGenics, Research, Rockville, MD, USA.; Zymeworks, Vancouver, British Columbia, Canada.
Source: Nature medicine [Nat Med] 2023 Nov; Vol. 29 (11), pp. 2814-2824. Date of Electronic Publication: 2023 Oct 19.
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1546-170X
DOI:10.1038/s41591-023-02593-0